BPC-157 Oral Tablets

BPC-157 Oral Tablets Oral Delivery Profile

BPC-157 Oral Tablets represents an advanced oral delivery system, engineered to survive gastrointestinal degradation and provide systemic biological activity without the need for traditional parenteral injection.

Pharmacological Architecture

Parameter	Value
Molecular Formula	C62H98N16O22
Molecular Mass	1419.5 g/mol
Assay Purity	>98.5%
Appearance	White enteric-coated capsules

Figure 1: BPC-157 Oral Tablets GI Tract Dissolution & Absorption

Oral Mechanism of Action

Detailed cascade of actions from ingestion to systemic effect:

1. Delivers the famous Body Protection Compound 157 via an acid-stable oral formulation.
2. Its unique gastric stability allows it to survive stomach acid at full pH 1.0 levels.
3. Binds directly to the intestinal lining initiating localized VEGF-driven angiogenesis.
4. Repairs intestinal tight junctions — massively restoring 'leaky gut' barrier function.
5. Triggers downstream systemic healing effects including dopamine and serotonin receptor normalization.

Figure 2: Rate of Oral Systemic Bioavailability

Primary Research Results

• Outcome 1: The go-to oral formulation for severe gut permeability and NSAID-induced ulceration research.
• Outcome 2: Works symbiotically with injectable BPC-157 to create a 'systemic + localized' healing approach.
• Outcome 3: Demonstrates potent gastroprotective effects even under extreme ethanol and aspirin challenge testing.

Gastric Pentadecapeptide: Natural Oral Stability

BPC-157 oral tablets leverage the peptide’s extraordinary natural stability in gastric juice. BPC-157 (Body Protection Compound-157) is derived from a protective protein found in human gastric juice, and unlike virtually all other peptides, it resists degradation by pepsin and hydrochloric acid for over 24 hours in vitro. This intrinsic gastric stability makes BPC-157 one of the only peptides in research that maintains bioactivity after oral administration without requiring specialized protective formulation technologies.

1. BPC-157’s pentadecapeptide structure (15 amino acids) contains no disulfide bonds or labile residues susceptible to acid hydrolysis at gastric pH (1.5–3.5).
2. The peptide resists pepsin cleavage due to its compact secondary structure and the absence of preferred pepsin cleavage sites (Phe-Phe, Phe-Tyr).
3. After gastric transit, BPC-157 is absorbed through intestinal paracellular and transcellular pathways, achieving systemic bioavailability.
4. Oral BPC-157 has demonstrated equivalent efficacy to intraperitoneal injection in multiple preclinical models including gastric ulcer, colitis, and liver injury.
5. The gut-first exposure allows high local concentrations at the gastrointestinal mucosa before systemic distribution, favoring GI-targeted research.

Oral Research Applications

• GI Healing: Oral BPC-157 is the preferred route for gastric ulcer, NSAID gastropathy, IBD, and intestinal anastomosis healing research, delivering the peptide directly to the target tissue.
• Gut-Brain Axis: Oral administration accesses enteric nervous system targets and vagal afferent pathways relevant to the gut-brain axis and CNS protection studies.
• Convenience: Tablets eliminate injection requirements, making BPC-157 accessible for longer-duration chronic administration protocols.
• Dosing: Oral research doses are typically 2–4x higher than equivalent injectable doses to account for incomplete absorption, despite the favorable gastric stability.
• Storage: Tablets are stable at room temperature in desiccated packaging. No reconstitution or refrigeration required, simplifying multi-site research logistics.